AbbVie (ABBV) Payables (2012 - 2026)

AbbVie has disclosed Payables across 15 years of filings, most recently posting $33.8 billion for Q1 2026.

• In Q1 2026, Payables rose 3.49% year-over-year to $33.8 billion; the TTM figure through Mar 2026 stood at $33.8 billion (up 3.49% YoY), while the FY2025 annual figure was $37.2 billion, up 16.55% from the prior year.
• Payables fell to $33.8 billion in Q1 2026, from $37.2 billion in the prior quarter.
• Over the last five years, Payables for ABBV reached as high as $37.4 billion in Q3 2025 and fell as low as $22.6 billion in Q2 2022.
• The 5-year median for Payables is $30.5 billion (2024), against an average of $29.7 billion.
• The widest YoY moves for Payables: up 26.38% in 2024, down 2.81% in 2024.
• A 5-year view of Payables shows it stood at $25.4 billion in 2022, then increased by 20.66% to $30.6 billion in 2023, then increased by 4.23% to $31.9 billion in 2024, then increased by 16.55% to $37.2 billion in 2025, then retreated by 9.29% to $33.8 billion in 2026.
• According to Business Quant data, Payables over the past three periods registered $33.8 billion, $37.2 billion, and $37.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.